-
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
17 Apr 2024 19:53 GMT
On Tuesday, Johnson & Johnson JNJ reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.
The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21 …
-
Johnson & Johnson (NYSE:JNJ) Q1 2024 Earnings Call Transcript
17 Apr 2024 12:58 GMT
Johnson & Johnson (NYSE:JNJ) Q1 2024 Earnings Call Transcript April 16, 2024
Johnson & Johnson isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to …
-
Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
16 Apr 2024 18:49 GMT
JNJ earnings call for the period ending March 31, 2024.
Image source: The Motley Fool.
Johnson & Johnson (JNJ -1.90%)
Q1 2024 Earnings Call
Apr 16, 2024, 8:30 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:
…
-
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
16 Apr 2024 15:01 GMT
In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $88.7B – $89.1B / $88.9B (instead of: $88.7B – $89.1B / $88.0B). …
-
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
05 Apr 2024 07:00 GMT
… INFORMATION I SHOULD KNOW ABOUT XARELTO®?
XARELTO® may cause serious side effects … at www.janssen.com/johnson-johnson-innovative-medicine. Janssen Research … .com/news-releases/johnson--johnson-to-showcase-its-broad-scientific …
-
Weeks after closing Bristol Myers deal, Karuna's ex-CEO heads to Blackstone-backed Anthos
22 Apr 2024 20:51 GMT
How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech.
Meury has been appointed CEO at Anthos Therapeutics, just over a month after closing Karuna Therapeutics’ sale to Bristol Myers Squibb. …
-
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
09 Apr 2024 09:07 GMT
… I SHOULD KNOW ABOUT XARELTO®?
XARELTO® may cause serious side … long you should take XARELTO®.
XARELTO® may need to be … POSSIBLE SIDE EFFECTS OF XARELTO®?
XARELTO® may cause serious side … www.janssen.com/johnson-johnson-innovative-medicine. Follow us …
-
Johnson & Johnson: A Clean Bill Of Health
28 Feb 2024 23:18 GMT
poba Summary Despite its greatly improved financial position following the spin-off of Kevenue Inc. (KVUE), Johnson & Johnson (NYSE:JNJ) continues to trade in line with its historical trading multiples. With the company set to deliver mid-single-digit …
-
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript
25 Jan 2024 14:40 GMT
Johnson & Johnson (NYSE:JNJ) Q4 2023 Earnings Call Transcript January 23, 2024
Johnson & Johnson beats earnings expectations. Reported EPS is $2.29, expectations were $2.27. Johnson & Johnson isn’t one of the 30 most popular stocks among hedge …
-
Johnson & Johnson reports robust quarter, but full-year earnings slip
24 Jan 2024 01:04 GMT
Adjusted earnings per share for the quarter came in at $2.29, surpassing expectations by a narrow margin.
For the full year, Johnson & Johnson reported sales of $85.2bn, representing a 6.5% growth rate.
However, full-year earnings per share decreased …